FTLP15

Across TCGA pan-cancer cohorts, FTLP15 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of FTLP15’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FTLP15 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FTLP15 is over-expressed in tumor, although a few such as BRCA and UCEC show the opposite, repressed pattern.

KIRC, BRCA, and LIHC are the cancer types where FTLP15 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FTLP15 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.682	<.001	12	view →
BRCA	All	III,IV	−0.203	.004	4	view →
LIHC	All	All	+0.098	.014	4	view →
UCEC	All	All	−0.649	.002	2	view →
STAD	All	II,III,IV	+0.206	.008	2	view →
KICH	Male	III,IV	−0.140	.033	1	view →
THCA	Male	All	−0.125	.024	1	view →
LUSC	All	All	−0.088	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

FTLP15–KIRC

Open the KIRC breakdown →